Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUVAMER phase 1/2 study of hydroxyurea + valproic acid or 6-mercaptopurine + valproic acid in AML or high-risk MDS unfit for standard chemotherapy
2022-501992-15-00Phase 2Authorised
- Sponsor
- Helse Bergen
- Start
- May 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of hydroxyurea, valproic acid and mercaptopurine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (4 cohorts), sponsored by Helse Bergen. Primary endpoints: Safety and tolerability, Clinical benefit for hydroxyurea + valproic acid and 2 more. Planned start May 2023; status: authorised.
02
Drugs
hydroxyureavalproic acidmercaptopurine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2022-501992-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501992-15-00.